| __timestamp | PTC Therapeutics, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44820000 | 1860000 |
| Thursday, January 1, 2015 | 82080000 | 2963000 |
| Friday, January 1, 2016 | 97130000 | 6961000 |
| Sunday, January 1, 2017 | 121271000 | 11779000 |
| Monday, January 1, 2018 | 153548000 | 13697000 |
| Tuesday, January 1, 2019 | 202541000 | 15749000 |
| Wednesday, January 1, 2020 | 245164000 | 18638000 |
| Friday, January 1, 2021 | 285773000 | 27196000 |
| Saturday, January 1, 2022 | 325998000 | 31739000 |
| Sunday, January 1, 2023 | 332540000 | 33491000 |
Cracking the code
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining financial health. Over the past decade, PTC Therapeutics, Inc. and Protagonist Therapeutics, Inc. have shown contrasting approaches to handling these costs. From 2014 to 2023, PTC Therapeutics saw a staggering 642% increase in SG&A expenses, peaking at $332 million in 2023. In contrast, Protagonist Therapeutics maintained a more conservative growth, with a 1,700% increase, reaching $33 million in the same year.
While PTC Therapeutics' expenses are significantly higher, reflecting its larger scale and market presence, Protagonist Therapeutics' leaner approach may appeal to investors seeking efficiency. This comparison highlights the strategic choices companies make in balancing growth and cost management, offering valuable insights for stakeholders in the biotech industry.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Protagonist Therapeutics, Inc.
Amgen Inc. and Protagonist Therapeutics, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Insmed Incorporated vs PTC Therapeutics, Inc.
Alkermes plc or PTC Therapeutics, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs PTC Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Rhythm Pharmaceuticals, Inc. and PTC Therapeutics, Inc.
Who Optimizes SG&A Costs Better? PTC Therapeutics, Inc. or Celldex Therapeutics, Inc.
Selling, General, and Administrative Costs: Xenon Pharmaceuticals Inc. vs Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. or Agios Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Protagonist Therapeutics, Inc. vs Evotec SE: SG&A Expense Trends